EE200000660A - Valk farnesüültransferaasi ja HMG CoA reduktaasi inhibiitorite kombinatsioonid ja nende kasutamine vähi raviks - Google Patents
Valk farnesüültransferaasi ja HMG CoA reduktaasi inhibiitorite kombinatsioonid ja nende kasutamine vähi raviksInfo
- Publication number
- EE200000660A EE200000660A EEP200000660A EEP200000660A EE200000660A EE 200000660 A EE200000660 A EE 200000660A EE P200000660 A EEP200000660 A EE P200000660A EE P200000660 A EEP200000660 A EE P200000660A EE 200000660 A EE200000660 A EE 200000660A
- Authority
- EE
- Estonia
- Prior art keywords
- cancer
- combinations
- treatment
- coa reductase
- reductase inhibitors
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 108010054353 p21(ras) farnesyl-protein transferase Proteins 0.000 title 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8520298P | 1998-05-12 | 1998-05-12 | |
| US9225398P | 1998-07-10 | 1998-07-10 | |
| PCT/US1999/010188 WO1999058505A2 (en) | 1998-05-12 | 1999-05-10 | Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200000660A true EE200000660A (et) | 2002-04-15 |
Family
ID=26772425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200000660A EE200000660A (et) | 1998-05-12 | 1999-05-10 | Valk farnesüültransferaasi ja HMG CoA reduktaasi inhibiitorite kombinatsioonid ja nende kasutamine vähi raviks |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6492410B1 (et) |
| EP (1) | EP1077949A2 (et) |
| JP (1) | JP2002514628A (et) |
| KR (1) | KR20010043529A (et) |
| CN (1) | CN1171874C (et) |
| AP (1) | AP2000001984A0 (et) |
| AU (1) | AU758891B2 (et) |
| BG (1) | BG105003A (et) |
| BR (1) | BR9911785A (et) |
| CA (1) | CA2331295A1 (et) |
| EA (1) | EA003860B1 (et) |
| EE (1) | EE200000660A (et) |
| GE (1) | GEP20032996B (et) |
| HR (1) | HRP20000771A2 (et) |
| HU (1) | HUP0102322A3 (et) |
| ID (1) | ID27933A (et) |
| IL (1) | IL139502A0 (et) |
| IS (1) | IS5713A (et) |
| NO (1) | NO20005680L (et) |
| NZ (1) | NZ508357A (et) |
| OA (1) | OA11551A (et) |
| PL (1) | PL344662A1 (et) |
| SK (1) | SK16742000A3 (et) |
| WO (1) | WO1999058505A2 (et) |
| YU (1) | YU68900A (et) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2363088A1 (en) * | 1999-02-11 | 2000-08-17 | Patrick T. Prendergast | Methods for treating viral infections |
| US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| US20020010128A1 (en) * | 2000-04-13 | 2002-01-24 | Parks Thomas P. | Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| US20020132781A1 (en) * | 2000-10-06 | 2002-09-19 | George Kindness | Combination and method of treatment of cancer utilizing a COX-2 inhibitor and A 3-hydroxy-3-methylglutaryl-coenzyme-A (HMG-CoA) reductase inhibitor |
| GB0220885D0 (en) * | 2002-09-09 | 2002-10-16 | Novartis Ag | Organic compounds |
| WO2005042710A1 (en) * | 2003-10-28 | 2005-05-12 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of statin to kill ebv-transformed b cells |
| SG166829A1 (en) * | 2005-11-08 | 2010-12-29 | Ranbaxy Lab Ltd | Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| KR100930365B1 (ko) * | 2006-11-09 | 2009-12-08 | 덕성여자대학교 산학협력단 | 심바스타틴을 유효성분으로 함유하는 유방암 치료용 약학적조성물 |
| US20080119444A1 (en) * | 2006-11-16 | 2008-05-22 | Steven Lehrer | Methods and compositions for the treatment of cancer |
| US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK523288A (da) * | 1987-10-06 | 1989-04-07 | Hoffmann La Roche | Aminosyrederivater |
| NL9002031A (nl) | 1990-09-14 | 1992-04-01 | Voskuilen Woudenberg Bv | Inrichting voor het bewerken van een uitwendig buisoppervlak. |
| US5571792A (en) * | 1994-06-30 | 1996-11-05 | Warner-Lambert Company | Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase |
| KR19990028303A (ko) * | 1995-06-22 | 1999-04-15 | 한센 핀 베네드, 안네 제헤르 | 성장호르몬 방출 특성을 가지는 화합물 |
| JPH11508262A (ja) | 1995-06-22 | 1999-07-21 | バイオジェン，インコーポレイテッド | Ｃｄ４０リガンドのフラグメントの結晶およびその使用 |
| UA57081C2 (uk) * | 1997-06-16 | 2003-06-16 | Пфайзер Продактс Інк. | Фармацевтична композиція для лікування раку або доброякісних проліферативних хвороб у ссавців, спосіб лікування, фармацевтична композиція для інгібування ненормального росту клітин у ссавців та спосіб інгібування |
-
1999
- 1999-05-10 GE GEAP19995670A patent/GEP20032996B/en unknown
- 1999-05-10 WO PCT/US1999/010188 patent/WO1999058505A2/en not_active Ceased
- 1999-05-10 BR BR9911785-1A patent/BR9911785A/pt not_active IP Right Cessation
- 1999-05-10 YU YU68900A patent/YU68900A/sh unknown
- 1999-05-10 IL IL13950299A patent/IL139502A0/xx unknown
- 1999-05-10 HU HU0102322A patent/HUP0102322A3/hu unknown
- 1999-05-10 AU AU39792/99A patent/AU758891B2/en not_active Ceased
- 1999-05-10 US US09/674,818 patent/US6492410B1/en not_active Expired - Fee Related
- 1999-05-10 HR HR20000771A patent/HRP20000771A2/hr not_active Application Discontinuation
- 1999-05-10 NZ NZ508357A patent/NZ508357A/xx unknown
- 1999-05-10 EP EP99922898A patent/EP1077949A2/en not_active Withdrawn
- 1999-05-10 ID IDW20002583A patent/ID27933A/id unknown
- 1999-05-10 CA CA002331295A patent/CA2331295A1/en not_active Abandoned
- 1999-05-10 KR KR1020007012632A patent/KR20010043529A/ko not_active Ceased
- 1999-05-10 EE EEP200000660A patent/EE200000660A/et unknown
- 1999-05-10 JP JP2000548309A patent/JP2002514628A/ja active Pending
- 1999-05-10 CN CNB99807649XA patent/CN1171874C/zh not_active Expired - Fee Related
- 1999-05-10 EA EA200001164A patent/EA003860B1/ru not_active IP Right Cessation
- 1999-05-10 PL PL99344662A patent/PL344662A1/xx not_active Application Discontinuation
- 1999-05-10 OA OA1200000310A patent/OA11551A/en unknown
- 1999-05-10 AP APAP/P/2000/001984A patent/AP2000001984A0/en unknown
- 1999-05-10 SK SK1674-2000A patent/SK16742000A3/sk unknown
-
2000
- 2000-11-10 IS IS5713A patent/IS5713A/is unknown
- 2000-11-10 NO NO20005680A patent/NO20005680L/no not_active Application Discontinuation
- 2000-11-29 BG BG105003A patent/BG105003A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA003860B1 (ru) | 2003-10-30 |
| NO20005680D0 (no) | 2000-11-10 |
| HRP20000771A2 (en) | 2001-06-30 |
| CN1171874C (zh) | 2004-10-20 |
| NO20005680L (no) | 2001-01-10 |
| AU3979299A (en) | 1999-11-29 |
| YU68900A (sh) | 2002-12-10 |
| IL139502A0 (en) | 2001-11-25 |
| OA11551A (en) | 2004-05-24 |
| PL344662A1 (en) | 2001-11-19 |
| WO1999058505A3 (en) | 2000-01-06 |
| SK16742000A3 (sk) | 2001-07-10 |
| JP2002514628A (ja) | 2002-05-21 |
| WO1999058505A2 (en) | 1999-11-18 |
| BG105003A (en) | 2001-07-31 |
| AU758891B2 (en) | 2003-04-03 |
| BR9911785A (pt) | 2001-04-03 |
| EA200001164A1 (ru) | 2001-06-25 |
| HUP0102322A2 (hu) | 2001-11-28 |
| US6492410B1 (en) | 2002-12-10 |
| IS5713A (is) | 2000-11-10 |
| ID27933A (id) | 2001-05-03 |
| GEP20032996B (en) | 2003-06-25 |
| EP1077949A2 (en) | 2001-02-28 |
| HUP0102322A3 (en) | 2001-12-28 |
| NZ508357A (en) | 2002-09-27 |
| CN1306515A (zh) | 2001-08-01 |
| CA2331295A1 (en) | 1999-11-18 |
| AP2000001984A0 (en) | 2000-12-31 |
| KR20010043529A (ko) | 2001-05-25 |
| HK1038355A1 (en) | 2002-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR1100403A (pt) | Composto e composição farmacêutica de inibidores de cox-2 | |
| EP1037641A4 (en) | LURE OF THE TRANSCRIPTION FACTOR AND INHIBITOR OF TUMOR GROWTH | |
| FI970990A7 (fi) | Syövän toteaminen ja hoito | |
| DK1021410T3 (da) | Prostaglandinagonister og deres anvendelse til behandling af knogletilstande | |
| NO20020635D0 (no) | Proteinpolymeriseringsinhibitorer og fremgangsmåter for anvendelse | |
| EE200100373A (et) | Bensoheterotsüklid ja nende kasutamine MEK inhibiitoritena | |
| EE200000488A (et) | Fosfolipaasensüümide inhibiitorid ja farmatseutilised kompositsioonid | |
| NO985652D0 (no) | Anvendelse av naaladaseinhibitorer ved behandling av kreft | |
| BR9508886A (pt) | Compostos e métodos para o tratamento de câncer | |
| NO20000996L (no) | Kombinasjonsterapi omfattende atorvastatin og et antihypertensivt middel | |
| EP0888458A4 (en) | COMBINATION OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCER | |
| NO20001323D0 (no) | Dipeptid-apoptose inhibitorer og deres anvendelse | |
| AU3000297A (en) | Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy | |
| NO20015516L (no) | Preparater og anvendelser av ET743 for behandling av kreft | |
| EE9900121A (et) | Farmatseutiline preparaat prostata hüpertroofia ja prostatakartsinoomi raviks | |
| UA66793C2 (uk) | Лептин як стримувач швидкого збільшення пухлини клітини | |
| NO994309D0 (no) | FremgangsmÕter for undertrykkelse av tumorvekst med kombinasjoner av isoprenoider og statiner | |
| NO20005680D0 (no) | Kombinasjoner av protein-farnesyltransferase og HMG CoA reduktase inhibitorer og anvendelse derav for behandling av cancer | |
| NO996206D0 (no) | Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer | |
| PT1079818E (pt) | Composicao compreendendo il-18 e topotecano para o tratamento e /ou prevencao de cancro | |
| NO20006626D0 (no) | Beleggingsmiddel og anvendelse herav | |
| AU2002340251A1 (en) | Use of mx gtpases in the prognosis and treatment of cancer | |
| ID28797A (id) | Tioredoksin dan pemrosesan biji-bijian | |
| EE200300057A (et) | Koostis vähi profülaktikaks ja raviks | |
| DE69900802D1 (de) | MnMgCuZn-Ferrit und dessen Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC1A | Change of owner name |